- Home
- NHS vs PROF Comparison
NHS vs PROF Comparison
Compare NHS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- PROF
- Stock Information
- Founded
- NHS 2003
- PROF N/A
- Country
- NHS United States
- PROF Canada
- Employees
- NHS N/A
- PROF N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- PROF Medical/Dental Instruments
- Sector
- NHS Finance
- PROF Health Care
- Exchange
- NHS Nasdaq
- PROF Nasdaq
- Market Cap
- NHS 221.6M
- PROF 201.2M
- IPO Year
- NHS N/A
- PROF N/A
- Fundamental
- Price
- NHS $7.79
- PROF $7.48
- Analyst Decision
- NHS
- PROF Strong Buy
- Analyst Count
- NHS 0
- PROF 2
- Target Price
- NHS N/A
- PROF $11.40
- AVG Volume (30 Days)
- NHS 111.8K
- PROF 102.1K
- Earning Date
- NHS 01-01-0001
- PROF 03-06-2025
- Dividend Yield
- NHS 13.44%
- PROF N/A
- EPS Growth
- NHS N/A
- PROF N/A
- EPS
- NHS N/A
- PROF N/A
- Revenue
- NHS N/A
- PROF $8,984,000.00
- Revenue This Year
- NHS N/A
- PROF $56.56
- Revenue Next Year
- NHS N/A
- PROF $151.33
- P/E Ratio
- NHS N/A
- PROF N/A
- Revenue Growth
- NHS N/A
- PROF 39.35
- 52 Week Low
- NHS $6.95
- PROF $5.63
- 52 Week High
- NHS $9.17
- PROF $11.42
- Technical
- Relative Strength Index (RSI)
- NHS 56.68
- PROF 65.75
- Support Level
- NHS $7.75
- PROF $5.63
- Resistance Level
- NHS $7.88
- PROF $6.36
- Average True Range (ATR)
- NHS 0.06
- PROF 0.36
- MACD
- NHS 0.01
- PROF 0.18
- Stochastic Oscillator
- NHS 70.00
- PROF 87.26
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.